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with lactic acid bacteria
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Background: Secondary hyperoxaluria either based on increased intestinal absorption of oxalate (enteric), or high
oxalate intake (dietary), is a major risk factor of calcium oxalate urolithiasis. Oxalate-degrading bacteria might have
beneficial effects on urinary oxalate excretion resulting from decreased intestinal oxalate concentration and absorption.
Methods: Twenty healthy subjects were studied initially while consuming a diet normal in oxalate. Study participants
were then placed on a controlled oxalate-rich diet for a period of 6 weeks. Starting with week 2 of the oxalate-rich diet,
participants received 2.6 g/day of a lactic acid bacteria preparation for 5 weeks. Finally, subjects were examined 4 weeks
after treatment while consuming again a normal-oxalate diet. Participants provided weekly 24-hour urine specimens.
Analyses of blood samples were performed before and at the end of treatment.
Results: Urinary oxalate excretion increased significantly from 0.354 ± 0.097 at baseline to 0.542 ± 0.163 mmol/24 h
under the oxalate-rich diet and remained elevated until the end of treatment, as did relative supersaturation of calcium
oxalate. Plasma oxalate concentration was significantly higher after 5 weeks of treatment compared to baseline.
Four weeks after treatment, urinary oxalate excretion and relative supersaturation of calcium oxalate fell to reach
initial values.
Conclusions: Persistent dietary hyperoxaluria and increased plasma oxalate concentration can already be induced
in healthy subjects without disorders of oxalate metabolism. The study preparation neither reduced urinary oxalate
excretion nor plasma oxalate concentration. The preparation may be altered to select for lactic acid bacteria strains
with the highest oxalate-degrading activity.
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Dietary hyperoxaluria, Calcium oxalate stone formationBackground
Calcium oxalate is the major constituent of about 75%
of all urinary stones [1]. Secondary hyperoxaluria either
based on intestinal hyperabsorption of oxalate, i.e.
enteric hyperoxaluria, or high intake of oxalate, i.e. dietary
hyperoxaluria, is considered a primary risk factor in the
pathogenesis of calcium oxalate urolithiasis. The impact
of dietary oxalate in the development of calcium oxalate
stone formation is unclear. It has been suggested that
dietary oxalate contributes up to 50% of urinary oxalate
excretion [2]. Estimates of normal dietary oxalate intake
are in the range of 50 to 200 mg daily, but may exceed
1000 mg per day if oxalate-rich foods are ingested [3-5].* Correspondence: Roswitha.Siener@ukb.uni-bonn.de
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stated.Analysis of the oxalate content of different foods by reliable
methods revealed a considerable number of foods with high
oxalate concentrations, e.g. spinach, rhubarb, sorrel,
sesame, carambola, almonds or wheat bran [4,6,7]. The
oxalate content of foods may vary according to growth
conditions and preparation methods [6,8]. However, a
study in healthy subjects revealed no significant increase
in the relative urinary supersaturation of calcium oxalate
under a vegetarian diet despite an increased oxalate intake
[9]. Moreover, a prospective study reported only a modest
positive association between dietary oxalate intake and the
risk for incident stone formation [5].
Colonization with oxalate-degrading bacteria in the
intestine may contribute to a decrease in urinary oxalate
excretion through reduction of intestinal concentration
of oxalate available for absorption [10]. Previous studiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Siener et al. Journal of Translational Medicine 2013, 11:306 Page 2 of 7
http://www.translational-medicine.com/content/11/1/306demonstrated that lactic acid bacteria are able to de-
grade oxalate in vitro and to reduce urinary oxalate
excretion in patients with idiopathic as well as enteric
hyperoxaluria [11,12]. However, two recent studies in
calcium oxalate stone formers with mild hyperoxaluria
failed to find a beneficial effect of the same lactic acid bac-
teria preparation (Oxadrop, VSL Pharmaceuticals, Rome,
Italy) on urinary oxalate excretion and calcium oxalate
supersaturation [13,14].
Aim of this study was to examine the effect of oral
administration of the lactic acid bacteria preparation
on dietary hyperoxaluria, plasma oxalate concentration and
the relative urinary supersaturation of calcium oxalate in
healthy subjects under controlled standardized conditions.
Thus, a major challenge for this study was the induction
of hyperoxaluria by high dietary intake of oxalate.
Subjects and methods
Subjects
A total of 20 healthy subjects, including 10 women and 10
men participated in the study. Inclusion criteria required
that participants (a) did not have a medical history of stone
formation or overt gastrointestinal diseases, (b) showed no
evidence of stone formation or other urinary tract diseases
in current renal ultrasound, (c) had normal kidney function
and (d) urinary oxalate excretion < 0.5 mmol/24 h prior to
the study. Each subject had a normal physical examination
and normal findings from multiparameter urine test strips
(Combur9-Test, Roche Diagnostics GmbH, Mannheim,
Germany). The subjects took no medication, including
antibiotics, at least 4 weeks prior to and during the study.
The study was approved by the ethics committee of the
Medical Faculty of the University of Bonn (reference
number 098/02). Written informed consent was obtained
from each participant before trial onset.
Study procedure
The study design is summarized in Table 1. Subjects were
studied at baseline while consuming a diet normal in
oxalate (approximately 100 mg oxalate/d). Diets were
individualized to avoid a strict regimen that is not feasible
for a long period, but remained constant for oxalate-
containing foods for the duration of the study. Study
participants were then placed on a controlled, oxalate-rich
diet (approximately 600 mg oxalate/d) for a period of sixTable 1 Study design
Controlled diet Normal-oxalate diet
Phase Baseline Control
Week Week 0 Week 1 Week 2
Lactic acid bacteria X
24 h-urine X X X
Blood sample Xweeks. Therefore, 150 ml of pure rhubarb juice, containing
approximately 500 mg oxalate, was consumed in addition
to the normal-oxalate baseline diet. Rhubarb juice was
chosen because standardization of dietary oxalate intake
can easily be achieved. Rhubarb juice was ingested at
lunch, a common time for the consumption of oxalate-rich
foods. The rhubarb juice was well tolerated. Starting with
week 2 of the oxalate-rich diet, the subjects took one
packet q.d. (2.6 g/d) of a lactic acid bacteria preparation
(Oxadrop, VSL Pharmaceuticals, Rome, Italy) for five
weeks. Subjects were instructed to take the preparation at
breakfast. Finally, subjects were examined four weeks after
treatment while consuming again a diet normal in oxalate
as at baseline (approximately 100 mg oxalate/d).
The composition of the diet was assessed by a 7-day
weighed dietary record. The subjects provided a detailed
description of types and weighed amounts of all food
items consumed. Subjects were asked to maintain a similar
diet during the study. Dietary records were used by study
participants to replicate dietary intake and collected by the
investigator to verify oxalate intake through analysis of the
oxalate content of foods. A blood sample was obtained at
baseline and at the end of treatment with the study prepar-
ation (week 6). In addition, 24-hour urines were weekly
collected during the study. Renal ultrasound examinations
were performed at baseline and after the treatment period
to exclude either stone formation or nephrocalcinosis.
Study preparation
Each gram of the lactic acid bacteria mixture (Oxadrop,
VSL Pharmaceuticals, Rome, Italy) contained 3.6 × 1011
CfU (Lactobacillus acidophilus, Bifidobacterium infantis,
Streptococcus thermophilus and Lactobacillus brevis). The
study preparation was kept refrigerated at 4°C and admin-
istered at breakfast.
Dietary oxalate concentration
To assure dietary oxalate intake, the oxalate contents of
foods were measured. For the determination of total oxalate
concentration, oxalate was extracted with 2 N hydrochloric
acid from homogenized samples. Analysis of filtrates
was performed by the HPLC-enzyme-reactor method
[15]. Oxalate was separated from matrix substances by an
anion exchange column (AS4A-DIONEX, ThermoFisher
Scientific, Waltham, Massachusetts). The mobile phaseOxalate-rich diet Normal-oxalate diet
Intervention Follow-up
Week 3 Week 4 Week 5 Week 6 Week 10
X X X X
X X X X X
X
Table 2 Characteristics of healthy subjects (mean ± standard
deviation)
Total Men Women P
(n = 20) (n = 10) (n = 10) M vs. W
Age (years) 29.1 ± 9.3 29.6 ± 12.3 28.6 ± 5.3 0.147
Height (cm) 176 ± 10 183 ± 8 169 ± 5
Weight (kg) 70 ± 12 78 ± 11 63 ± 7
BMI (kg/m2) 22.6 ± 2.0 23.2 ± 2.0 22.0 ± 1.9 0.199
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with 0.3 mol/l NaOH. The enzyme reactor contained 5
units of immobilized oxalate oxidase (oxalate oxidase:
Sigma Diagnostics, St. Louis, USA) (carrier: VA Epoxy
Biosynth, Riedel-de-Häen, Seelze, Germany) which oxi-
dized oxalate to carbon dioxide and hydrogen peroxide.
Resulting hydrogen peroxide was analyzed by amperometric
detection.
Plasma oxalate concentration and serum profile
Plasma oxalate concentration was measured using an
HPLC enzyme reactor method [16]. Blood samples were
obtained in lithium heparin tubes and immediately centri-
fuged at 1600 rpm (1000 × g) for 10 min at 4°C. Ultrafiltra-
tion was carried out in a Centrisart-I-tube (cut off 20,000
D, Sartorius, Germany) at 3900 rpm (2500 × g) for 50 min.
at 4°C. To remove proteins and macromolecules, 0.5 mL
plasma was added to 0.5 mL distilled water in the outer
tube. To prevent in vitro generation of oxalate, 12.5 μL of
1 N hydrochloric acid was added to the inner tube. The
yielded ultrafiltrate was analyzed for oxalate concentration
using HPLC enzyme reactor. Analysis of serum parameters
was performed by routine methods.
24 h urinary excretion profiles
Urine volume, pH (potentiometry) and concentrations of
creatinine (Jaffé reaction), sodium, potassium and chloride
(indirect ion selective electrode), calcium (cresolphthalein
complex), magnesium (methylthymol blue), inorganic
sulfate (nephelometry), inorganic phosphate (phosphate
molybdate reaction), ammonium (ion selective electrode),
citrate (enzymatically, citrate lyase), uric acid (enzymatically,
uricase), and oxalate (enzymatically, oxalate oxidase) were
measured. Laboratory quality certification was available for
each parameter. The relative supersaturation of calcium
oxalate (RS CaOx) was determined using EQUIL2 [17].
Statistics
Comparisons between groups were performed using the
Mann–Whitney U-test for non-parametric unpaired data.
Differences between values at baseline, control, intervention
and follow-up were evaluated by the two-tailed Wilcoxon
matched pairs signed rank test. Data are presented as
means ± standard deviation. All reported P values are
two-sided. Differences were considered significant at
p < 0.05. Statistical analysis was performed using IBM
Statistical Package for the Social Sciences version 21.0
(SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the study participants are listed
in Table 2. There were 20 healthy subjects, 10 men and 10
women, of a mean age of 29 ± 9 years (range 22 – 62 years)
and a mean body mass index (BMI) of 23 ± 2 kg/m2 (range20 – 27 kg/m2). Mean age and BMI did not differ between
men and women.
Table 3 shows urinary parameters. Urinary oxalate
excretion increased significantly from 0.354 ± 0.097 at
baseline on the normal-oxalate diet to 0.542 ± 0.163 mmol/
24 h after 1 week under the controlled oxalate-rich diet, as
did relative supersaturation of calcium oxalate. All other
urinary parameters, except urinary chloride excretion, did
not change. No consistent change in any urinary parameter
occurred during administration of the study drug com-
pared to control. Changes were observed in exceptional
cases regarding urinary potassium (week 2), and citrate
excretion (week 6), possibly due to small variations in
dietary composition. The lactic acid bacteria preparation
was well tolerated. No subject had any abdominal discom-
fort or did complain about other adverse events. During
follow-up (week 10) under controlled normal-oxalate diet,
urinary oxalate excretion and relative supersaturation of
calcium oxalate fell to reach initial values.
Blood parameters are listed in Table 4. Plasma oxalate
concentration was significantly higher under the oxalate-
rich diet during administration of the lactic acid bacteria
preparation (week 6) compared to baseline. All other
parameters did not differ significantly. The statistically
significant difference in serum cholesterol concentration
between intervention and baseline is not considered
clinically relevant.
Discussion
The results of our study clearly reveal the role of dietary
oxalate as a major determinant of urinary oxalate excretion.
The present data demonstrate that an oxalate-rich diet can
induce persistent hyperoxaluria already in healthy subjects
without disturbances of oxalate metabolism or gastrointes-
tinal diseases. The daily consumption of an oxalate-rich diet
with an oxalate content of approximately 600 mg resulted
in a significant increase in urinary oxalate excretion from
0.354 ± 0.097 at baseline under the normal-oxalate diet to
0.542 ± 0.163 mmol/24 h during control by 0.188 mmol/
24 h (> 50%), corresponding to 35% of total urinary oxalate
excretion. Taking into account that an additional propor-
tion of urinary oxalate comes from the basal diet normal in
oxalate, a higher percentage of urinary oxalate excretion
may derive from the diet than has been previously assumed
Table 3 Urinary parameters at baseline, before (control), during (intervention) and after administration (follow-up) of the study preparation (n = 20; mean ±
standard deviation)
Baseline Control Intervention Follow-up P P P P
Diet Normal-oxalate Oxalate-rich Oxalate-rich Oxalate-rich Normal-oxalate
Week Week 0 Week 1 Week 2 Week 6 Week 10 Wk 0 vs. 1 Wk 1 vs. 2 Wk 1 vs. 6 Wk 0 vs. 10
Volume (mL/24 h) 2,379 ± 1,063 2,396 ± 858 2,322 ± 997 2,534 ±1,311 2,433 ± 1,194 0.888 0.550 0.526 0.765
pH 6.38 ± 0.37 6.36 ± 0.31 6.39 ± 0.38 6.39 ± 0.41 6.39 ± 0.21 0.365 0.823 0.667 0.926
Sodium (mmol/24 h) 157 ± 74 182 ± 51 155 ± 65 173 ± 58 179 ± 74 0.100 0.107 0.398 0.204
Potassium (mmol/24 h) 65 ± 29 71 ± 19 82 ± 24 77 ± 28 74 ± 23 0.287 0.044 0.190 0.232
Calcium (mmol/24 h) 4.02 ± 1.83 4.11 ± 1.70 3.85 ± 1.54 4.09 ± 1.51 4.47 ± 2.16 0.881 0.411 0.808 0.334
Magnesium (mmol/24 h) 5.14 ± 2.06 5.18 ± 1.95 4.68 ± 1.75 4.99 ± 1.87 5.56 ± 2.73 0.970 0.262 0.881 0.351
Ammonium (mmol/24 h) 28.1 ± 9.1 26.6 ± 7.2 28.0 ± 8.3 29.8 ± 9.4 30.0 ± 11.8 0.351 0.526 0.218 0.940
Chloride (mmol/24 h) 147 ± 71 178 ± 48 161 ± 68 158 ± 53 182 ± 82 0.026 0.391 0.070 0.052
Phosphate (mmol/24 h) 26.9 ± 8.6 28.2 ± 7.5 28.8 ± 7.7 31.7 ± 10.5 27.4 ± 9.8 0.478 0.681 0.135 0.881
Sulphate (mmol/24 h) 20.5 ± 6.5 20.7 ± 6.7 22.2 ± 5.9 23.4 ± 5.7 20.6 ± 5.2 0.881 0.218 0.161 0.852
Creatinine (mmol/24 h) 12.43 ± 3.50 13.46 ± 4.87 13.19 ± 4.28 13.27 ± 4.22 12.53 ± 3.97 0.232 0.563 0.279 0.940
Uric acid (mmol/24 h) 3.10 ± 0.90 3.27 ± 1.01 3.16 ± 0.74 3.35 ± 0.73 3.16 ± 0.89 0.305 0.681 0.370 0.695
Oxalate (mmol/24 h) 0.354 ± 0.097 0.542 ± 0.163 0.563 ± 0.183 0.638 ±0.197 0.371 ± 0.108 < 0.001 0.563 0.052 0.455
Citrate (mmol/24 h) 3.662 ± 1.567 3.553 ± 1.123 3.640 ± 1.517 3.969 ± 1.461 3.444 ± 1.233 0.526 0.970 0.021 0.279

















Table 4 Blood parameters at baseline (week 0) and end of
intervention (week 6) (n = 20; mean ± standard deviation)
Baseline Intervention
Week Week 0 Week 6 P
Sodium (mmol/L) 139 ± 2 139 ± 2 0.861
Potassium (mmol/L) 4.48 ± 0.40 4.44 ± 0.45 0.598
Calcium (mmol/L) 2.36 ± 0.07 2.35 ± 0.12 0.587
Chloride (mmol/L) 103 ± 2 103 ± 3 0.759
Magnesium (mmol/L) 0.82 ± 0.07 0.81 ± 0.06 0.079
Creatinine (mg/dL) 0.96 ± 0.15 0.95 ± 0.13 0.513
Urea (mg/dL) 26 ± 6 26 ± 5 0.779
Uric acid (mg/dL) 4.7 ± 1.0 4.7 ± 0.9 0.276
Triglycerides (mg/dL) 82 ± 38 89 ± 36 0.184
Cholesterol (mg/dL) 192 ± 26 185 ± 27 0.046
HDL (mg/dL) 67 ± 16 64 ± 15 0.354
LDL (mg/dL) 109 ± 26 103 ± 24 0.056
Leucocytes (G/L) 5.78 ± 1.60 5.87 ± 1.42 0.672
Erythrocytes (T/L) 5.0 ± 0.3 4.94 ± 0.32 0.599
Hemoglobin (g/dL) 14.9 ± 1.1 14.8 ± 1.0 0.615
Hematokrit (%) 44 ± 3 44 ± 3 0.524
Thrombocytes (G/L) 223 ± 48 235 ± 48 0.077
Oxalate (μmol/L) 1.19 ± 0.80 2.85 ± 2.38 0.002
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dietary oxalate may contribute up to 50% of urinary oxalate
excretion in healthy individuals [2].
Our results agree with findings of Hess et al., who
reported that urinary oxalate excretion increased to
only 0.780 mmol/24 h following the ingestion of a diet
rich in oxalate and normal in calcium (2220 mg oxalate
and 1211 mg calcium per day) [19]. In the present study,
the ingestion of 500 mg of oxalate per day resulted in
the absorption of only 3.4% of the additional food derived
oxalate. The suppressed absorption of oxalate that is
apparent at high oxalate intake is compatible with results
of Holmes et al., who calculated that for an intake of 50,
180 and 250 mg oxalate per 2500 kcal/day, the increase in
urinary oxalate excretion corresponds to the absorption
of 15.1, 6.6 and 5.8%, respectively, of the dietary oxalate
[2]. Our results suggest that there is a limit in oxalate
absorption, as urinary oxalate does not continuously rise
even if dietary oxalate is further increased.
Urinary oxalate concentration plays a crucial role in
determining the risk of calcium oxalate stone formation.
Because the oxalate/calcium molar ratio in urine is
normally 1:10, even small variations in urinary oxalate
concentration exert much greater changes in relative
supersaturation of calcium oxalate, crystallization and
the risk of stone formation than comparable variations
in urinary calcium concentration. Thus, the relativesupersaturation of calcium oxalate increased significantly
under the oxalate-rich diet.
Previous studies suggested that lactic acid bacteria could
lower urinary oxalate excretion. A study conducted by
Campieri et al. showed that a variety of lactic acid bacteria
are able to degrade oxalate in vitro, at least to a modest
degree [11]. The mixture of bacterial strains in Oxadrop
were also selected for their ability to degrade oxalate
in vitro [11]. However, the administration of the lactic acid
bacteria preparation in this study in healthy subjects
did not affect urinary oxalate excretion. At least two
mechanisms are ascribed to the presence of lactic acid
bacteria that use oxalate in their metabolism: decrease in
intestinal oxalate concentration by degradation of oxalate
and decrease in oxalate absorption. Because urinary oxalate
excretion did not vary during intervention with the study
preparation under the controlled oxalate-rich diet, it is
unlikely that the lactic acid bacteria preparation decreased
intestinal oxalate concentration and/or absorption. Although
a previous small study in six patients with idiopathic
calcium oxalate urolithiasis and mild hyperoxaluria as
well as a study in ten calcium oxalate stone formers with
enteric hyperoxaluria found that lactic acid bacteria may
reduce urinary oxalate excretion [11,12], two recent
studies in calcium oxalate stone formers with mild hyper-
oxaluria under controlled conditions were unable to find a
beneficial effect of Oxadrop on urinary oxalate excretion
and calcium oxalate supersaturation [13,14]. Importantly,
the dosage used in these trials was similar to that used in
the present study, which was 9.4 × 1011 bacteria.
On the contrary to our results, two studies conducted on
the lactic acid preparation VSL#3 (Sigma Tau Pharmaceuti-
cals, Gaithersburg, USA), which is similar but not identical
in its lactic acid bacteria content and composition to
Oxadrop, revealed a significant fall in urinary oxalate
excretion and estimated oxalate absorption in healthy
subjects [20,21]. However, major study limitations should
be considered. Whereas the first study reported an
extremely high mean baseline absorption of 31% in healthy
subjects, which rather seems to be characteristic for
patients with enteric hyperoxaluria secondary to intestinal
diseases and/or resection [20], in the second study, intes-
tinal oxalate absorption was assessed only at the 6-hour
post-oxalate ingestion period [21]. Moreover, in both
studies urinary oxalate excretion was not assessed for the
complete 24-hour post-ingestion period.
Since previous studies of Oxadrop also failed to dem-
onstrate an effect [13,14], the preparation may be altered
to select specifically for oxalate-degrading strains of lactic
acid bacteria. A study in 60 Lactobacillus strains belonging
to 12 species found a high variability in the oxalate-
degrading capacity in the different species [22]. Strains of
Lactobacillus acidophilus showed the highest oxalate-
degrading activity, whereas Lactobacillus brevis exhibited
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bacillus and Bifidobacterium spp. rather than Oxalobacter
formigenes may protect black South Africans against
calcium oxalate stone disease due to the increased diversity
and abundance of these oxalate-degrading strains and low
abundance of Oxalobacter formigenes in this group [23].
A limitation of our study regarding the presumed lesser
ability of the lactic acid bacteria preparation compared
with Oxalobacter formigenes to directly metabolize oxalate
is the possibility that the high oxalate diet has overcome
the ability of the preparation to demonstrate an effect. It is
unknown whether Oxadrop might have an effect in the
current study population if the subjects had been studied
on a normal-oxalate diet. However, the administration
of the oxalate-rich diet was required to induce dietary
hyperoxaluria and to achieve adequate intestinal growth
and activity of the oxalate-degrading lactic acid bacteria
in Oxadrop, as has been shown in animal studies with
Oxalobacter formigenes [24]. Moreover, studies, confirming
the ability of the study preparation to survive passage
through extremely acidic environments, such as the human
stomach, and to be present in the location where oxalate
absorption occurs, are lacking.
To our knowledge, studies examining the effect of
administration of lactic acid bacteria on plasma oxalate
concentrations are lacking. The plasma oxalate concentra-
tion in healthy subjects ranges between 1 and 16 μmol/L
and are found to be age-related with lower concentrations
in younger subjects [16]. Plasma oxalate concentrations
are significantly higher in patients with primary hyper-
oxaluria, especially, when the glomerular filtration rate
declines and chronic kidney failure becomes obvious [25].
In the present study, the ingestion of the oxalate-rich diet
resulted in an increase in plasma oxalate concentration
already in healthy subjects. Because lactic acid bacteria
preparation did not affect urinary oxalate excretion, and
hence intestinal oxalate absorption, it can be assumed
that a high percentage of plasma oxalate is derived from
the diet.
Conclusions
The current study suggests that persistent dietary hyperox-
aluria can already be induced in healthy subjects without
disturbances of oxalate metabolism simply by ingestion of
foods with high oxalate content. The lactic acid bacteria
preparation used in our study did not reduce urinary
oxalate excretion. Interestingly and surprisingly, plasma
oxalate concentration increased under the controlled
oxalate-rich diet irrespective of the administration of
the lactic acid bacteria preparation. Despite evidence in
the literature that lactic acid bacteria may play a role in
the therapy of calcium oxalate stone formers with
idiopathic or enteric hyperoxaluria, we were not able to
show effectiveness of these bacteria in the treatment ofdietary hyperoxaluria in healthy subjects. Therefore, the
preparation may be altered to select for lactic acid bacteria
strains with the highest oxalate-degrading activity.
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